Meeting
2014 ASCO Annual Meeting
Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib.
Authors
Friedegund Elke Meier
University of Tuebingen, Tuebingen, Germany
Friedegund Elke Meier , Claus Garbe , Keiran Smalley , Keith Flaherty , Dirk Schadendorf , Stefan Beissert , Dagmar Kulms , Heike Niessner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 9062)
DOI
10.1200/jco.2014.32.15_suppl.9062
Abstract #
9062
Poster Bd #
266
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).
First Author: Matthew Dankner
Poster
2011 ASCO Annual Meeting
Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 in BRAFV600E melanoma cells through regulation of endoplasmic reticulum stress-related genes.
First Author: F. E. Meier
Poster
2023 ASCO Annual Meeting
Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib.
First Author: Paul B. Chapman
Poster
2017 ASCO Annual Meeting
Atezolizumab (A) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity.
First Author: Ryan J. Sullivan